Trial Profile
Effect of alemtuzumab administered in combination with fludarabine and melphalan in patients who received unrelated donor allografts
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 May 2015
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Fludarabine; Melphalan
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 25 May 2015 New trial record